Healthcare / Medical Instruments & SuppliesTaiwan
$324.50
+2.00 (+0.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 24%
FCF escenarios
weak_data · normalized FCF $747.3M · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
60/100
B
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$24.9B
P/E
15.7x
↓EV/EBITDA
8.7x
↓ROE
14.0%
↑Gross Margin
52.3%
↑Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.7%
FCF CAGR
+22.7%
FCF margin
16.2%
FCF / Net income
0.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.04B · net income $1.63B · FCF $1.14B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.04B | $7.04B | $6.82B | $6.79B | $6.32B |
| Net Income | $1.63B | $1.63B | $1.83B | $1.66B | $1.54B |
| EBITDA | $2.85B | $2.85B | $2.92B | $2.96B | $2.77B |
| EPS | — | — | 23.24 | 22.61 | 21.84 |
| Gross Margin | 52.3% | 52.3% | 56.1% | 54.0% | 52.4% |
| Operating Margin | 25.7% | 25.7% | 30.0% | 29.8% | 28.7% |
| Net Margin | 23.1% | 23.1% | 26.9% | 24.4% | 24.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.09 | 0.16 | 0.16 |
| Current Ratio | 1.48 | 1.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.14B | $1.14B | $747.3M | $-484.8M | $618.0M |
| Returns | |||||
| ROE | 14.0% | 14.0% | 16.7% | 16.7% | 24.0% |
| Valuation | |||||
| P/E | 15.74 | 15.74 | 16.52 | 17.36 | 18.60 |
| EV/EBITDA | 8.70 | 8.70 | 10.02 | 9.72 | 10.05 |
| P/B | 2.18 | 2.18 | 2.76 | 2.90 | 4.46 |
| Growth & Yield | |||||
| Revenue Growth | 3.3% | 3.3% | 0.4% | 7.4% | — |
| EPS Growth | — | — | 2.8% | 3.5% | — |
| Dividend Yield | 3.1% | 3.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.6%
Start / end P/E
n/dx → n/dx
EPS bridge
23.24 → n/d
Residual
-7.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.